Adding ribociclib, a targeted drug that disrupts cancer cells, to standard hormone therapy was found to boost survival among premenopausal patients who have an advanced form of the disease. The research, led by Dr Sara Hurvitz of the University of California in Los Angeles, followed pre-menopausal women under the age of 59 who had advanced hormone receptor-positive, HER2-negative breast cancer. The patients were assigned either ribociclib, which targets and interferes with processes in the cells that cause cancer to grow, or a placebo.
Researchers around the world are working to find better ways to preventdetectand treat breast cancer, and to improve the quality of life of patients and survivors. Studies continue to uncover lifestyle factors and habits, as well as inherited genes, that affect breast cancer risk. Here are a few examples:.
Approximately 3. The outlook for non-metastatic breast cancer patients has overall improved, with an average five-year survival rate reaching close to percent for people with stage 0 or I breast cancer, and 93 percent for people with stage II breast cancer. The prognosis for those women diagnosed with metastatic breast cancer is not as promising.
We round up some of the latest developments in treatments for people with secondary breast cancer. Our ambition as a charity is to stop breast cancer deaths, and this can only be achieved by improving treatments for secondary breast cancer. Last year saw results released from several clinical trials which are finding better ways to keep secondary breast cancer under control.
This is an exciting time in metastatic breast cancer research. Many new treatments for metastatic breast cancer are under study and treatment is improving. Findings from clinical trials will determine whether or not new treatments will become a part of standard care for metastatic breast cancer.
Several accomplishments have been achieved in triple-negative breast cancer TNBC research over the last year. The phase III IMpassion trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheless, despite encouraging results being obtained in this trial, many open questions remain.
More Information. Content on this page was created or selected by the Everyday Health Media team and is funded by an advertising sponsor. The sponsor may select the topic but does not edit the content.
NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat breast cancer. They are also looking at how to address disparities and improve quality of life for survivors of the disease. MRI magnetic resonance imagingultrasoundand clinical breast exams are also used to detect breast cancer, but not as routine screening tools. Ongoing studies are looking at ways to enhance current breast cancer screening options.
Breast cancer BC is the most common malignancy in women. It is classified into a few major molecular subtypes according to hormone and growth factor receptor expression. Over the past few years, substantial advances have been made in the discovery of new drugs for treating BC.